 Dr. Jonathan Ahn at the University of Washington and his collaborators have FDA approval to study rapamycin in adults 50 and older with gum disease, which may offer clues for treating or slowing down other age-related conditions. So we're hoping that rapamycin can target the underlying cause, which is aging, to improve patients that have periodontal disease.